Descripción del proyecto
Una prueba bioquímica para el diagnóstico de los traumatismos craneoencefálicos
Los médicos delos servicios de urgencias llegan al diagnóstico de un presunto traumatismo craneoencefálico (TCE) mediante una combinación de TAC y resonancia magnética nuclear, así como una evaluación neurológica. El equipo del proyecto Medicortex, financiado con fondos europeos, ha elaborado un método alternativo de diagnóstico de los TCE que es rápido y fácil de usar, puede realizarse en el centro de atención y ofrece resultados inmediatos. La prueba se basa en biomarcadores específicos del TCE que pueden detectarse en muestras de saliva y orina, y tiene un gran potencial para mejorar el desenlace clínico de millones de personas con TCE en todo el mundo.
Objetivo
Traumatic Brain Injury (TBI) is the leading cause of central nervous system impairment, over traumatic spinal cord injury. Mild and moderate TBI cases represent more than 90% of TBI injuries but are unfortunately the most difficult to accurately diagnose. Currently, standard TBI diagnostic tools are based on CT scans, MRI scans or cognitive evaluations which are not always sufficient accurate to correctly diagnose mild and moderate cases, putting the patient at risks (long-term consequences of untreated TBI include headache, dizziness, irritability, anxiety and depression).
Medicortex is an innovative point of care test based on novel glycan-based biomarkers. The Medicortex diagnostic kit is a cost-efficient, quick and reliable test based on specific biomarkers for the identification of TBI in both saliva and urine samples. We have protected the innovation with several patents.
Many biomarkers have been suggested for TBI but none has resulted in an approved test. We have already proven that our biomarker is strongly correlated with TBI, allowing us to address a TBI point of care (POC) diagnostics market that will exceed €2 billion annually.
We will sell the Medicortex TBI tests and envision a price to distributors of €25. We expect distributors to charge €50 to healthcare providers and make a margin of 50%. This will reduce the TBI diagnostics cost by a factor of 10-25x for healthcare systems as a single test can be charged to the patient for less than €100 instead of €1,000 for a CT scan or €2,500 for an MRI scan. Two distributors have confirmed they interest in a letter.
Our Founder Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Our Medical Director Dr. Mårten Kvist is active in academia and our Head of R&D Dr. Lasse Välimaa has a track record in R&D of bioanalytical methods and medical diagnostics.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
20520 TURKU
Finlandia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.